Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD

Blood

Volumn 124, Issue 12, 2014, Pages 1941-1950

  Awojoodu, Anthony O ^a   Keegan, Philip M ^a   Lane, Alicia R ^b   Zhang, Yuying ^a   Lynch, Kevin R ^c   Platt, Manu O ^a   Botchwey, Edward A ^a  

^a Emory University   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CERAMIDE; FIBRINOGEN RECEPTOR; GLYCOPHORIN A; INTERLEUKIN 1BETA; INTERLEUKIN 6; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; CELL ADHESION MOLECULE; HEMOGLOBIN S; ICAM4 PROTEIN, HUMAN; LYSOPHOSPHOLIPID; SPHINGOLIPID; SPHINGOSINE 1-PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL SIZE; COCULTURE; CONFOCAL MICROSCOPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; INFLAMMATORY CELL; INTERNALIZATION; MACROPHAGE; MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SICKLE CELL; SICKLE CELL ANEMIA; SPHINGOLIPID METABOLISM; UMBILICAL VEIN ENDOTHELIAL CELL; WILD TYPE; ANALOGS AND DERIVATIVES; ANEMIA, SICKLE CELL; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; ERYTHROCYTE DISORDER; GENETICS; INFLAMMATION; MUTANT MOUSE STRAIN; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; CELL ADHESION; CELL ADHESION MOLECULES; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ERYTHROCYTES, ABNORMAL; HEMOGLOBIN, SICKLE; HUMANS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE;

EID: 84907200779     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-543652     Document Type: Article

References (53)

1. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol 2012; 59(13):1123-1133.
2. Ohanian J, Ohanian V. Sphingolipids in mammalian cell signalling. Cell Mol Life Sci 2001; 58(14):2053-2068.
3. López DJ, Egido-Gabas M, López-Montero I, et al. Accumulated bending energy elicits neutral sphingomyelinase activity in human red blood cells. Biophys J 2012; 102(9):2077-2085.
4. Olivera A, Allende ML, Proia RL. Shaping the landscape: metabolic regulation of S1P gradients. Biochim Biophys Acta 2013; 1831(1):193-202.
5. Golan K, Vagima Y, Ludin A., et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 2012; 119(11):2478-2488.
6. Walter DH, Rochwalsky U, Reinhold J., et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 2007; 27(2):275-282.
7. Awojoodu AO, Ogle ME, Sefcik L.S., et al. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc Natl Acad Sci USA 2013; 110(34):13785-13790.
8. Ishii M, Kikuta J, Shimazu Y., Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010; 207(13):2793-2798.
9. Dinkla S, Wessels K, Verdurmen W.P., et al. Functional consequences of sphingomyelinase-induced changes in erythrocyte membrane structure. Cell Death Dis 2012; 3:e410.
10. Cuschieri J, Bulger E, Billgrin J., Garcia I, Maier RV. Acid sphingomyelinase is required for lipid Raft TLR4 complex formation. Surg Infect (Larchmt) 2007; 8(1):91-106.
11. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009; 21(6): 836-846.
12. Wong ML, Xie B, Beatini N., et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000; 97(15):8681-8686.
13. Marathe S, Schissel SL, Yellin M.J., et al. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998; 273(7):4081-4088.
14. Sakata A, Ochiai T, Shimeno H., et al. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 2007; 122(1):54-64.
15. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 2013; 122(24):3892-3898.
16. Zolla L, D'Alessandro A. An efficient apparatus for rapid deoxygenation of erythrocyte concentrates for alternative banking strategies. J Blood Transfus. 2013; 2013:896537.
17. Shaner RL, Allegood JC, Park H, et al. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 2009; 50(8):1692-1707.
18. Kaul DK, Fabry ME, Windisch P, Baez S., Nagel RL. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest 1983; 72(1):22-31.
19. Xu R, Sun W, Jin J., Obeid LM, Mao C. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J 2010; 24(7):2507-2515.
20. Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 2007; 21(4):1202-1209.
21. Shet AS. Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag 2008; 4(4):769-774.
22. Allan D, Limbrick AR, Thomas P, Westerman MP. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature. 1982; 295(5850):612-613.
23. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol 2004; 77(4):323-328.
24. Rosen H, Gonzalez-Cabrera PJ, Sanna M.G., Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009; 78:743-768.
25. Hebbel RP, Schwartz RS, Mohandas N. The adhesive sickle erythrocyte: cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haematol 1985; 14(1): 141-161.
26. Zennadi R, Chien A, Xu K., Batchvarova M, Telen MJ. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008; 112(8):3474-3483.
27. Zennadi R, Whalen EJ, Soderblom E.J., et al. Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood 2012; 119(5): 1217-1227.
28. Vince RV, Chrismas B, Midgley A.W., McNaughton LR, Madden LA. Hypoxia mediated release of endothelial microparticles and increased association of S100A12 with circulating neutrophils. Oxid Med Cell Longev 2009; 2(1):2-6.
29. Tantawy AA, Adly AA, Ismail E.A., Habeeb NM, Farouk A. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: relation to cardiovascular complications. Platelets 2013; 24(8):605-614.
30. Shet AS, Aras O, Gupta K., et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102(7):2678-2683.
31. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107(9): 1047-1057.
32. Urbina P, Flores-Díaz M, Alape-Girón A, Alonso A, Goñi FM. Effects of bilayer composition and physical properties on the phospholipase C and sphingomyelinase activities of Clostridium perfringens a-toxin. Biochim Biophys Acta. 2011; 1808(1):279-286.
33. Opreanu M, Tikhonenko M, Bozack S., et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes 2011; 60(9): 2370-2378.
34. Bhatia R, Matsushita K, Yamakuchi M., Morrell CN, Cao W, Lowenstein CJ. Ceramide triggers Weibel-Palade body exocytosis. Circ Res 2004; 95(3):319-324.
35. Barrett O Jr, Saunders DE Jr, McFarland DE, Humphries JO. Myocardial infarction in sickle cell anemia. Am J Hematol 1984; 16(2):139-147.
36. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol. 2010; 42(6):716-724.
37. Trajkovic K, Hsu C, Chiantia S., et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319(5867):1244-1247.
38. Camus SM, Gausserès B, Bonnin P., et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood 2012; 120(25):5050-5058.
39. Bardelli C, Amoruso A, Federici Canova D, et al. Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARg ligands. Br J Pharmacol 2012; 165(3):716-728.
40. Vasina EM, Cauwenberghs S, Staudt M., et al. Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013; 3(2): 107-123.
41. Barry OP, Praticò D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998; 102(1):136-144.
42. Zhang Y, Berka V, Song A., et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest 2014; 124(6):2750-2761.
43. Fueller M, Wang DA, Tigyi G, Siess W. Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell Signal 2003; 15(4):367-375.
44. Safaya S, Steinberg MH, Klings ES. Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-κB signaling pathway. Mol Immunol 2012; 50(1-2):117-123.
45. Keegan PM, Surapaneni S, Platt MO. Sickle cell disease activates peripheral blood mononuclear cells to induce cathepsins k and v activity in endothelial cells. Anemia 2012; 2012:201781.
46. Harvey KA, Welch Z, Sliva D., Siddiqui RA. Role of Rho kinase in sphingosine 1-phosphate-mediated endothelial and smooth muscle cell migration and differentiation. Mol Cell Biochem 2010; 342(1-2):7-19.
47. Yogi A, Callera GE, Aranha A.B., et al. Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 2011; 57(4):809-818.
48. Fontana V, Jy W, Ahn E.R., et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008; 122(5):599-603.
49. Truman JP, Al Gadban MM, Smith KJ, et al. Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology 2012; 136(1): 30-45.
50. Jilani K, Enkel S, Bissinger R., Almilaji A, Abed M, Lang F. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013; 5(7):1230-1243.
51. Ozdogu H, Boga C, Sozer O., et al. The apoptosis of blood polymorphonuclear leukocytes in sickle cell disease. Cytometry B Clin Cytom 2007; 72(4): 276-280.
52. Weigert A, Cremer S, Schmidt M.V., et al. Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood 2010; 115(17):3531-3540.
53. Balreira A, Lacerda L, Miranda C.S., Arosa FA. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. Br J Haematol 2005; 129(5):667-676.